var data={"title":"LEVOleucovorin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">LEVOleucovorin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/86885?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levoleucovorin-patient-drug-information\" class=\"drug drug_patient\">see &quot;LEVOleucovorin: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=levoleucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;LEVOleucovorin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6268764\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fusilev</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063703\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Chemotherapy Modulating Agent;</li>\n      <li>\n        Rescue Agent (Chemotherapy)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063905\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Levoleucovorin, when substituted in place of leucovorin calcium (the racemic form), is dosed at <b>one-half</b> the usual dose of leucovorin calcium:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic:</b> IV: The following regimens have been used (in combination with fluorouracil; fluorouracil doses may need to be adjusted for toxicity; no adjustment is required for the levoleucovorin dose):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">100 mg/m<sup>2</sup>/day over at least 3 minutes (followed by fluorouracil 370 mg/m<sup>2</sup>/day) for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks depending on recovery from toxicities, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 mg/m<sup>2</sup>/day (followed by fluorouracil 425 mg/m<sup>2</sup>/day) for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks depending on recovery from toxicities, <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Substitution dosing:</i> Levoleucovorin, when substituted in place of leucovorin calcium within a chemotherapy regimen, is dosed at <b>one-half</b> the usual dose of leucovorin calcium (Goldberg 1997; Kovoor 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate rescue:</b> IV: Usual dose: 7.5 mg (~5 mg/m<sup>2</sup>) every 6 hours for 10 doses, beginning 24 hours after the start of the methotrexate infusion (based on a methotrexate dose of 12 g/m<sup>2</sup> IV over 4 hours). Levoleucovorin (and hydration and urinary alkalinization to pH &ge;7) should be continued and/or adjusted until the methotrexate level is &lt;0.05 micromolar (5 x 10<sup>-8</sup> M) as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Normal methotrexate elimination</i> (serum methotrexate levels ~10 micromolar at 24 hours post administration, 1 micromolar at 48 hours and &lt;0.2 micromolar at 72 hours post infusion): 7.5 mg IV every 6 hours for 10 doses </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed late methotrexate elimination</i> (serum methotrexate levels &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours post methotrexate infusion): Continue 7.5 mg IV every 6 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed early methotrexate elimination and/or evidence of acute renal injury</i> (serum methotrexate level &ge;50 micromolar at 24 hours, &ge;5 micromolar at 48 hours or a doubling or more of the serum creatinine level at 24 hours post methotrexate infusion [likely to develop reversible renal failure]): 75 mg IV every 3 hours until methotrexate level is &lt;1 micromolar, followed by 7.5 mg IV every 3 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Significant clinical toxicity in the presence of impaired methotrexate elimination or renal impairment (as described above):</i> Extend levoleucovorin treatment for an additional 24 hours (total of 14 doses) in subsequent treatment cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed methotrexate elimination due to third space fluid accumulation, renal insufficiency, or inadequate hydration:</i> May require higher levoleucovorin doses or prolonged administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist overdose:</b> IV: 7.5 mg (~5 mg/m<sup>2</sup>) every 6 hours; continue until the methotrexate level is &lt;0.01 micromolar (10<sup>-8</sup> M). Initiate treatment as soon as possible after methotrexate overdose. Increase the levoleucovorin dose to 50 mg/m<sup>2</sup> IV every 3 hours if the 24-hour serum creatinine has increased 50% over baseline, or if the 24 hour methotrexate level is &gt;5 micromolar (5 x 10<sup>-6</sup> M), or if the 48-hour methotrexate level is &gt;0.9 micromolar (9 x 10<sup>-7</sup> M); continue levoleucovorin until the methotrexate level is &lt;0.01 micromolar (10<sup>-8</sup> M). Hydration (aggressive) and urinary alkalinization (urinary pH &ge;7 with sodium bicarbonate) should also be maintained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impaired methotrexate elimination:</b> IV: 7.5 mg (~5 mg/m<sup>2</sup>) every 6 hours; continue until the methotrexate level is &lt;0.01 micromolar (10<sup>-8</sup> M). Initiate treatment within 24 hours of methotrexate administration if elimination is impaired. Increase the levoleucovorin dose to 50 mg/m<sup>2</sup> IV every 3 hours if the 24-hour serum creatinine has increased 50% over baseline, or if the 24-hour methotrexate level is &gt;5 micromolar (5 x 10<sup>-6</sup> M), or if the 48-hour methotrexate level is &gt;0.9 micromolar (9 x 10<sup>-7</sup> M); continue levoleucovorin until the methotrexate level is &lt;0.01 micromolar (10<sup>-8</sup> M). Hydration (aggressive) and urinary alkalinization (urinary pH &ge;7 with sodium bicarbonate) should also be maintained.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063904\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=levoleucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;LEVOleucovorin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Levoleucovorin, when substituted in place of leucovorin calcium (the racemic form),  is dosed at <b>one-half</b> the usual dose of leucovorin calcium: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate rescue:</b> Children  and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist overdose:</b> Children  and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impaired methotrexate elimination:</b> Children  and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063906\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265589\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no initial dosage adjustments provided in the manufacturer&rsquo;s labeling; in patients with impaired methotrexate elimination, adjust levoleucovorin dose based on methotrexate levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265590\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063912\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 175 mg/17.5 mL (17.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 175 mg/17.5 mL (17.5 mL); 250 mg/25 mL (25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fusilev: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 175 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063701\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063907\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration only; do not administer intrathecally. Administer by slow IV push or infusion over at least 3 minutes, not to exceed 160 mg/minute (due to calcium content).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For colorectal cancer: Levoleucovorin has also been administered (off-label administration rate) as IV infusion over 2 hours (Comella 2000; Tournigand 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063705\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, metastatic:</b> Palliative treatment of advanced, metastatic colorectal cancer (in combination with fluorouracil).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist overdose:</b> Antidote to diminish toxicity in inadvertent overdosage of folic acid antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate rescue:</b> Rescue agent after high-dose methotrexate therapy in osteosarcoma treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Impaired methotrexate elimination:</b> Antidote to diminish toxicity and counteract effects of impaired methotrexate elimination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Levoleucovorin is not indicated for the treatment of pernicious anemia or megaloblastic anemias secondary to the lack of vitamin B<sub>12</sub> (improper use may result in hematologic remission with progressive neurologic manifestations).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063697\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LEVOleucovorin may be confused with leucovorin calcium, Leukeran, Leukine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063883\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported with levoleucovorin either as a part of combination chemotherapy or following chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;29%), malaise (&le;29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (6% to 29%), alopecia (&le;26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Stomatitis (38% to 72%; grades 3/4: 6% to 12%), diarrhea (6% to 70%; grades 3/4: &le;19%), nausea (19% to 62%), vomiting (38% to 40%), anorexia (&le;24%), decreased appetite (&le;24%), abdominal pain (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;29%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Confusion (6%), neuropathy (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (6%), dyspepsia (6%), typhlitis (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Disruption of body temperature regulation, hypersensitivity reaction, pruritus, rigors, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063712\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Severe hypersensitivity or previous allergic reaction to leucovorin products, folinic acid, folic acid, or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063713\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Levoleucovorin and leucovorin calcium enhance the toxicity of fluorouracil. Deaths due to severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin calcium in combination with fluorouracil. Levoleucovorin is indicated in combination with fluorouracil for the palliative treatment of colorectal cancer; when administered together, the fluorouracil dose is reduced (compared to fluorouracil dosing without levoleucovorin). The typical fluorouracil gastrointestinal toxicities (eg, diarrhea, stomatitis) may be of greater severity or longer duration with fluorouracil and levoleucovorin combination therapy. Symptoms of gastrointestinal toxicity should be completely resolved prior to treatment (initial or repeat).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure/syncope: Seizures and/or syncope have been reported with leucovorin calcium; generally in patients with CNS metastases or other underlying risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly and/or debilitated patients are at higher risk for severe gastrointestinal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV patients: Concomitant use of leucovorin calcium and sulfamethoxazole-trimethoprim for the acute treatment of <i>pneumocystis jirovecii</i> pneumonia (PCP) in patients with HIV infection has been associated with increased rates of treatment failure and morbidity; may also occur with levoleucovorin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: For IV administration only; do not administer intrathecally. Due to calcium content, do not administer IV solutions at a rate &gt;160 mg levoleucovorin/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate: Methotrexate serum concentrations should be monitored to determine dose and duration of levoleucovorin therapy. Dose may need to be increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration, concurrent interacting medications). Although levoleucovorin may lessen hematologic toxicity due to methotrexate, it has no effect on other toxicities associated with methotrexate (eg, nephrotoxicity).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299596\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063888\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10324&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Tegafur. This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063707\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063708\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Levoleucovorin is the levo isomeric form of racemic leucovorin, a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063711\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if levoleucovorin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breastfeeding or to discontinue levoleucovorin, taking into account the importance of treatment to the mother. Levoleucovorin is the levo isomeric form of racemic leucovorin, a biologically active form of folic acid. Adequate amounts of folic acid are recommended in breastfeeding women. Refer to Folic Acid monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063909\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">High-dose methotrexate therapy, impaired methotrexate elimination, or methotrexate overdose (inadvertent): Serum methotrexate and creatinine levels at least once daily. Monitor urine pH. Monitor fluid and electrolyte status in patients with delayed methotrexate elimination (likely to experience renal toxicity). For colorectal cancer, monitor for diarrhea and stomatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063896\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Levoleucovorin counteracts the toxic (and therapeutic) effects of folic acid antagonists (eg, methotrexate) which act by inhibiting dihydrofolate reductase. Levoleucovorin is the levo isomeric and pharmacologic active form of leucovorin (levoleucovorin does not require reduction by dihydrofolate reductase). A reduced derivative of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Leucovorin enhances the activity (and toxicity) of fluorouracil by stabilizing the binding of 5-fluoro-2&rsquo;-deoxyuridine-5&rsquo;-monophosphate (FdUMP; a fluorouracil metabolite) to thymidylate synthetase resulting in inhibition of this enzyme.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6063898\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Converted to the active reduced form of folate, 5-methyl-tetrahydrofolate (5-methyl-THF; active)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Total-tetrahydrofolate: 5.1 hours; (6S)-5-methyl-5,6,7,8-tetrahydrofolate: 6.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IV (healthy volunteers; 15 mg dose): 0.9 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322879\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LEVOleucovorin Calcium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mg/17.5ml (17.5 mL): $896.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LEVOleucovorin Calcium PF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/25 mL (25 mL): $1,281.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Fusilev Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (LEVOleucovorin Calcium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $218.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mg (1): $387.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875343\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elvorine (BE);</li>\n      <li>Isovorin (AT, CH, DK, FI, GB, GR, IS, NL, NO, PT, SE, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Comella P, De Vita F, Mancarella S, et al. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. <i>Ann Oncol</i>. 2000;11:1323-1333.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/11106123/pubmed\" target=\"_blank\" id=\"11106123\">11106123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falcone A, Ricci S, Brunetti I, et al, &ldquo;Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,&rdquo; <i>J Clin Oncol</i>, 2007, 25(13):1670-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/17470860 /pubmed\" target=\"_blank\" id=\"17470860 \">17470860 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fusilev (levoleucovorin) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals; April 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldberg RM, Hatfield AK, Kahn M, et al, &ldquo;Prospectively Randomized North Central Cancer Treatment Group Trial of Intensive-Course Fluorouracil Combined With the l-Isomer of Intravenous Leucovorin, Oral Leucovorin, or Intravenous Leucovorin for the Treatment of Advanced Colorectal Cancer,&rdquo; <i>J Clin Oncol</i>, 1997, 15(11):3320-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/9363861/pubmed\" target=\"_blank\" id=\"9363861\">9363861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goorin A, Strother D, Poplack D, et al, &ldquo;Safety and Efficacy of l-leucovorin Rescue Following High-Dose Methotrexate for Osteosarcoma,&rdquo; <i>Med Pediatr Oncol</i>, 1995, 24(6):362-7.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/7715542/pubmed\" target=\"_blank\" id=\"7715542\">7715542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hempel G, Lingg R, and Boos J, &ldquo;Interactions of Carboxypeptidase G2 With 6S-Leucovorin and 6R-Leucovorin <i>in vitro</i>: Implications for the Application in Case of Methotrexate Intoxications,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2005, 55(4):347-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/15723260/pubmed\" target=\"_blank\" id=\"15723260\">15723260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaffe N, Jorgensen K, Robertson R, et al, &ldquo;Substitution of l-leucovorin for d,l-leucovorin in the Rescue from High-Dose Methotrexate Treatment in Patients With Osteosarcoma,&rdquo; <i>Anticancer Drugs</i>, 1993, 4(5):559-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/8292813/pubmed\" target=\"_blank\" id=\"8292813\">8292813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovoor PA, Karim SM, Marshall JL. Is levoleucovorin an alternative to racemic leucovorin? A literature review. <i>Clin Colorectal Cancer</i>. 2009;8(4):200-206. doi: 10.3816/CCC.2009.n.034.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/19822510/pubmed\" target=\"_blank\" id=\"19822510\">19822510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Labianca R, Cascinu S, Frontini L, et al, &ldquo;High-Versus Low-Dose Levo-Leucovorin as a Modulator of 5-Fluorouracil in Advanced Colorectal Cancer: A &lsquo;GISCAD&rsquo; Phase III Study,&rdquo; <i>Ann Oncol</i>, 1997, 8(2):169-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/9093726/pubmed\" target=\"_blank\" id=\"9093726\">9093726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levoleucovorin [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levoleucovorin [prescribing information]. Parsippany, NJ: Actavis; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levoleucovorin [prescribing information]. Princeton, NJ: Sandoz, Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levoleucovorin [prescribing information]. Rockford, IL: Mylan Institutional LLC; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mader RM, Steger GG, Rizovsky B, et al, &ldquo;Pharmacokinetics of Rac-Leucovorin vs [S]-Leucovorin in Patients With Advanced Gastrointestinal Cancer,&rdquo; <i>Br J Clin Pharmacol</i>, 1994, 37(3):243-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/8198932/pubmed\" target=\"_blank\" id=\"8198932\">8198932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scheithauer W, Kornek G, Marczell A, et al, &ldquo;Fluorouracil Plus Racemic Leucovorin Versus Fluorouracil Combined With the Pure L-Isomer of Leucovorin for the Treatment of Advanced Colorectal Cancer: A Randomized Phase III Study,&rdquo; <i>J Clin Oncol</i>, 1997, 15(3):908-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/9060527/pubmed\" target=\"_blank\" id=\"9060527\">9060527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. <i>J Clin Oncol</i>. 2006;24:394-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levoleucovorin-drug-information/abstract-text/16421419/pubmed\" target=\"_blank\" id=\"16421419\">16421419</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10324 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6268764\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6063703\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6063905\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6063904\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6063906\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16265589\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16265590\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6063912\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6063701\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6063907\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6063705\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6063697\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6063883\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6063712\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6063713\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299596\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6063888\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6063707\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6063708\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6063711\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6063909\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6063896\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6063898\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322879\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875343\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10324|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levoleucovorin-patient-drug-information\" class=\"drug drug_patient\">LEVOleucovorin: Patient drug information \t</a></li><li><a href=\"topic.htm?path=levoleucovorin-pediatric-drug-information\" class=\"drug drug_pediatric\">LEVOleucovorin: Pediatric drug information</a></li></ul></div></div>","javascript":null}